Compare IRMD & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRMD | GERN |
|---|---|---|
| Founded | 1992 | 1990 |
| Country | United States | United States |
| Employees | N/A | 229 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 2014 | N/A |
| Metric | IRMD | GERN |
|---|---|---|
| Price | $88.67 | $1.51 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 3 |
| Target Price | ★ $116.00 | $2.17 |
| AVG Volume (30 Days) | 78.2K | ★ 18.3M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.89% | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $83,814,000.00 | N/A |
| Revenue This Year | $12.38 | $26.91 |
| Revenue Next Year | $11.31 | $43.75 |
| P/E Ratio | $51.58 | ★ N/A |
| Revenue Growth | ★ 14.43 | N/A |
| 52 Week Low | $50.36 | $1.04 |
| 52 Week High | $107.90 | $2.01 |
| Indicator | IRMD | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 33.95 | 42.68 |
| Support Level | $82.64 | $1.41 |
| Resistance Level | $105.87 | $1.72 |
| Average True Range (ATR) | 2.73 | 0.10 |
| MACD | -0.45 | -0.02 |
| Stochastic Oscillator | 0.00 | 8.11 |
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold to hospitals and acute care facilities in the United States and internationally. It generates majority revenue from United States.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.